[Cost-effectiveness of newborn screening for cystic fibrosis]
Valcárcel-Nazco C, Oliva Hernández C, Velasco González V, Cuéllar-Pompa L, Castilla I, Vallejo-Torres L, Serrano-Aguilar P
Record ID 32018013061
Spanish
Original Title:
Coste-efectividad del cribado neonatal de fibrosis quística
Authors' objectives:
To determine the cost-effectiveness ratio of each of the main strategies for neonatal screening for cystic fibrosis in Spain.
Authors' results and conclusions:
RESULTS: Results of the economic evaluation model show that newborn screening for CF is an efficient alternative. The IRT+IRT+DNA screening strategy has a lower ICER compared with no screening (8,801.46 €/LYG and 4,024.85 €/QALY). The screening strategy with higher ICER is IRT+DNA+IRT (16,394.59 €/LYG y 7,497.14 €/QALY).
CONCLUSIONS: CF neonatal screening is an efficient alternative in terms of costeffectiveness from the perspective of the NHS, resulting in a profit on health outcomes of patients in both LYG and QALY.
Authors' methods:
We have performed a full economic evaluation that compares the costeffectiveness ratio of each of the main CF newborn screening strategies that are currently being carried out in Spain: IRT/IRT, IRT/DNA, IRT/IRT/DNA and IRT/DNA/IRT versus no screening. We have developed a decision tree with five main branches representing each strategy to be evaluated and the option of not screening the disease. The measures of effectiveness used were LYGs and QALYs. Both cost and effects were discounted at a rate of 3%. A WTP of € 30,000/LYG and € 30,000/QALY was considered. Costs were expressed in euros of 2013. A probabilistic sensitivity analysis was performed by means of Monte Carlo simulations, allowing us to compute the acceptability curves and the expected value of perfect information. To determine the parameters that caused greater variability in the model results, ANCOVA models were applied to Monte Carlo simulations.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
https://sescs.es/coste-efectividad-del-cribado-neonatal-de-fibrosis-quistica/
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Spain
MeSH Terms
- Neonatal Screening
- Cystic Fibrosis
- Infant, Newborn
- Cost-Effectiveness Analysis
Keywords
- Neonatal screening
- Cystic fibrosis
- Economic evaluation
Contact
Organisation Name:
Canary Health Service
Contact Address:
Dirección del Servicio. Servicio Canario de la Salud, Camino Candelaria 44, 1ª planta, 38109 El Rosario, Santa Cruz de Tenerife
Contact Name:
sescs@sescs.es
Contact Email:
sescs@sescs.es
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.